Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2009 - 2026)

Ionis Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $57.3 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 2503.82% year-over-year to $57.3 million; the TTM figure through Mar 2026 stood at $730.9 million (up 60.04% YoY), while the FY2025 annual figure was $675.8 million, up 41.37% from the prior year.
• Cash from Financing Activities was $57.3 million for Q1 2026 at Ionis Pharmaceuticals, down from $591.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $591.2 million in Q4 2025 to a low of -$51.0 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $105.9 million across 5 years, with a median of $2.6 million in 2024.
• Biggest YoY gain for Cash from Financing Activities was 11713.83% in 2023; the steepest drop was 1859.38% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$51.0 million in 2022, then soared by 179.82% to $40.7 million in 2023, then tumbled by 208.33% to -$44.1 million in 2024, then surged by 1440.05% to $591.2 million in 2025, then plunged by 90.31% to $57.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $57.3 million (Q1 2026), $591.2 million (Q4 2025), and $81.2 million (Q3 2025), per Business Quant data.